The EPS projection of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) for quarter ended 2016-09-30 is $0.16. Last week, the EPS forecast was $0.16 against target of $0.16, a month earlier. Two months ago, this estimate was $0.16 versus forecast of $0.16 three months earlier, implying a deviation of 0%.
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) stated that 18 days ago, its stock price was positively revised 2 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 1 , 3, 3, and 3, correspondingly.
EPS estimate downgrade for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) EPS target for the quarter closed 1 was $0.16, based on 5 recommendations. As reported on 2016-05-03 the EPS was $0.02. The change was $0, implying a percentage deviation of 0%. The projections showed a standard deviation of 0.04.
Quarterly Sales Estimates
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) yearly sales prediction for the fiscal 2016 stands at $103.056 and the median estimate is at $101.7. Almost 3 analysts issued sales target.
Highest sales target is $110.47 while the lowest target is $97 showing standard deviation of 6.836%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 2.316%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) announced that the deviation in forecast was 3.449%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...